GlassScriptPhysician profile
Yuen S Yee
NPI 1457488371
$2,987.37
in general payments reported to CMS, 2019-2025
23 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $23.91 · 2021: $23.97 · 2022: $107 · 2023: $196 · 2024: $1,641 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $630.22 | 2019-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $435.08 | 2023-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $285.88 | 2024-2025 | Voquezna |
| Genzyme Corporation | $184.48 | 2023-2024 | |
| Madrigal Pharmaceuticals | $184.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.65 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $145.81 | 2019-2025 | |
| Boston Scientific Corporation | $145.68 | 2021-2024 | Watchman Access System |
| Janssen Biotech, INC. | $134.67 | 2024-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $125.86 | 2024-2025 | Omvoh, Zepbound |
| Janssen Scientific Affairs, LLC | $110.74 | 2024 | |
| Celgene Corporation | $58.13 | 2024 | Zeposia |
| Gilead Sciences, INC. | $49.64 | 2019-2022 | |
| Braintree Laboratories, INC. | $47.86 | 2022-2024 | Suflave, Sutab |
| Qol Medical, LLC | $46.09 | 2025 | Sucraid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $45.68 | 2019 | |
| Ferring Pharmaceuticals INC. | $40.97 | 2019-2025 | Rebyota |
| Allergan, INC. | $40.66 | 2019 | |
| Olympus America INC. | $40.33 | 2022-2024 | Endoclot Phs |
| Aimmune Therapeutics, INC. | $35.90 | 2024-2025 | Zenpep |
| Medtronic, INC. | $30.91 | 2025 | Gi Genius |
| Erbe USA INC | $15.89 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,785.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuen Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.